These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33621770)

  • 1. Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study.
    Rodríguez-Osorio X; Lema-Facal T; Rubio-Nazábal E; Castro-Vilanova MD; Pato-Pato A; Abella-Corral J; Corredera E; López-Ferreiro A; Puy-Núñez A; López-González FJ
    Epilepsy Res; 2021 May; 172():106570. PubMed ID: 33621770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.
    Piña-Garza JE; Villanueva V; Rosenfeld W; Yoshinaga H; Patten A; Malhotra M
    Epilepsy Behav; 2022 Oct; 135():108901. PubMed ID: 36122531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
    Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ
    Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis.
    Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y;
    Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
    Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M
    Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
    Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
    CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Malhotra M; Patten A; Kaneko S
    Epilepsia Open; 2024 Apr; 9(2):501-512. PubMed ID: 37867420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of perampanel as adjunctive therapy among Chinese patients with focal-onset epilepsy: A real-world prospective observational study.
    Wang Q; Xu Y; Chen Y; Wu X; Ge Y; Zhu G
    Epilepsy Behav; 2022 Nov; 136():108937. PubMed ID: 36215830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
    Resnick T; Patten A; Ngo LY; Malhotra M
    Epilepsy Behav; 2022 Mar; 128():108528. PubMed ID: 35078116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative 12-month retention rate, effectiveness and tolerability of perampanel when used as a first add-on or a late add-on treatment in patients with focal epilepsies: The COM-PER study.
    Canas N; Félix C; Silva V; Arraiolos A; Fernandez-Llimos F
    Seizure; 2021 Mar; 86():109-115. PubMed ID: 33592505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.
    Rektor I; Krauss GL; Inoue Y; Kaneko S; Williams B; Patten A; Malhotra M; Laurenza A; Wechsler RT
    Epilepsia; 2020 Jul; 61(7):1491-1502. PubMed ID: 32645213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India.
    Mehndiratta MM; Gulhane M; Jabeen SA; Patten A; Dash A; Malhotra M
    Epilepsia Open; 2021 Mar; 6(1):90-101. PubMed ID: 33681652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective, real-world experience of perampanel monotherapy in patient with first new onset focal seizure: A Thailand experience.
    Chinvarun Y
    Epilepsia Open; 2022 Mar; 7(1):67-74. PubMed ID: 34741590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of perampanel monotherapy after adjunctive therapy through retention rate in subjects with focal-onset seizures with or without focal to bilateral tonic-clonic seizures: A multicenter retrospective study in Korea.
    Lim SC; Lee WG; Kim DW; Kim KK; Shon YM; Park J; Lee Y; Seo DW
    Epilepsy Behav; 2023 Aug; 145():109291. PubMed ID: 37336136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with inadequately controlled focal-onset seizures: Japanese subgroup analysis.
    Omatsu H; Watanabe T; Kira R; Ishiba K; Patten A; Takase T; Ngo LY
    Seizure; 2023 Aug; 110():109-116. PubMed ID: 37336055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.
    Fogarasi A; Flamini R; Milh M; Phillips S; Yoshitomi S; Patten A; Takase T; Laurenza A; Ngo LY
    Epilepsia; 2020 Jan; 61(1):125-137. PubMed ID: 31912493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy.
    Maguire M; Ben-Menachem E; Patten A; Malhotra M; Ngo LY
    Epilepsy Behav; 2022 Jan; 126():108483. PubMed ID: 34953337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perampanel as adjuvant treatment in epileptic encephalopathies: A multicenter study in routine clinical practice.
    Alonso-Singer P; Aguilar-Amat Prior MJ; Oliva-Navarro J; Massot-Tarrús A; Giráldez BG; Bermejo P; DeToledo-Heras M; Aledo-Serrano Á; Martínez-Cayuelas E; Tirado-Requero P; Velázquez-Fragua R; López-Sobrino G; Ojeda J
    Epilepsy Behav; 2022 Sep; 134():108836. PubMed ID: 35870432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
    Nishida T; Lee SK; Wu T; Tiamkao S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of perampanel as early add-on therapy in Chinese patients with focal-onset seizures: a multicenter, open-label, single-arm study.
    Gao L; Lu Q; Wang Z; Yue W; Wang G; Shao X; Guo Y; Yi Y; Hong Z; Jiang Y; Xiao B; Cui G; Gao F; Hu J; Liang J; Zhang M; Wang Y
    Front Neurol; 2023; 14():1236046. PubMed ID: 37712083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.